RESULTS: Luteolin inhibited the progression of rat prostate carcinogenesis by induction of apoptosis in the TRAP model. Luteolin decreased cell proliferation in a dose-dependent manner and induced apoptosis with activation of caspase-3 and 7 in CRPC cells. Dietary luteolin also suppressed tumor growth via induction of apoptosis and inhibition of angiogenesis in PCai1 and 22Rv1 xenograft models. Luteolin dramatically suppressed AR-V7 protein expression in 22Rv1 cells, and miR-8080 transduction decreased AR-V7 and induction of apoptosis in 22Rv1. Furthermore, miR-8080 knock-down abrogated the luteolin-dependent reduction of AR-V7 protein and cell growth. Induction of miR-8080 following luteolin intake enhanced the chemotherapeutic effect of enzalutamide in 22Rv1 xenografts.
INTRODUCTION AND OBJECTIVES:
Prostate cancer may eventually result in castration resistance in most metastatic cancer patients. Various drugs are used to prolong the survival, but they fail in achieving complete remission due to systemic adverse reactions. To overcome the limitations of those current therapies, we have developed a cell-specific drug delivery system (DDS) using in vivo phage display.
METHODS: The phage library was injected into C57BL/6 mice through the tail vein. Five minutes later, blood was recovered from the heart. Phages with low affinity for normal tissue remaining in the blood were collected. After amplification, the phages were injected into a new cohort of C57BL/6 mice. After three rounds of in vivo phage display in mice, we performed the same procedures in a cynomolgus monkey. Then, we performed in vivo phage display in a C.B-17 SCID mouse xenograft tumor model using the LNCaP cell lines to identify the specific peptides targeting cancer cells. After four rounds of in vivo phage display in C.B-17 SCID mice, the peptide sequences of the recovered phages were analyzed in order to identify peptide sequences that specifically bind to prostate cancer tissue. Three phages with the highest binding affinity were selected, and peptides were synthesized based on the amino acid sequences. These peptides were administered to LNCaP cell lines and xenograft SCID mice, and the binding affinity to each tissue was evaluated.
RESULTS: By the phage display, the homing peptides targeting to prostate cancer tissue were detected in thirty-two types of sequences. Three amino acid sequences candidates for homing peptides were identified. Through evaluation of the binding affinity to prostate cancer cells in vitro, peptides with the highest binding affinity among the three peptides could be identified. The peptides were confirmed to react specifically with cells of a prostate cancer cell line by analysis of binding affinity to the mouse organ.
CONCLUSIONS: We have identified novel cell-specific DDS peptide that bind to prostate cancer cells by in vivo phage display. 
